O3.8 Early Results: “ROCKET” a phase II Study of RRx-001, a novel triple epigenetic inhibitor, Resensitization to Irinotecan in Colorectal Cancer
Author:
C. Carter,T. Reid,G. Fisher,C. Cho-Phan,P. Kunz,H. Kaiser,B. Oronsky,G. Fanger,S. Caroen,C. Parker,J. Scicinski
Publication:
Annals of Oncology
Copyright © 2015 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.